Glycomimetics sets terms for $60M IPO; Cancer Genetics closes $46M offering;

@FierceBiotech: Popular on FierceCRO.com: InVentiv opens U.K. hub as EU demand climbs. Article | Follow @FierceBiotech

@JohnCFierce: The ax drops at troubled Merck as big restructuring gets underway. Story | Follow @JohnCFierce

@DamianFierce: Ex-Calistoga chief Gallagher joins VC Frazier Healthcare to steer biotech bets. News | Follow @DamianFierce

> Glycomimetics says it plans to sell four million shares at a price of $14 to $16 a share. Story

> Cancer Genetics ($CGIX) has closed a public offering of $46 million of shares. Release

> Numab AG says it has reacquired the rights to ND003, a bispecific anti-IL5RxCD3 antibody fragment for the targeted lysis of eosinophils in severe asthma, from Sucampo AG. Release

> Jupiter, FL-based Charleston Laboratories completed its Phase III clinical trial of CL-108 at the midway point after an independent monitoring committee determined that the study should be stopped because both efficacy endpoints of the study have been met. Release

Medical Device News

@FierceMedDev: DOD agency commits $70M to develop brain-monitoring implant. Item | Follow @FierceMedDev

@MarkHFierce: Apollo Endosurgery, a 2012 Fierce 15 winner, aims for big growth by snatching up Allergan's obesity device business. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: A blog post from the FDA late last week highlighted the agency's efforts to regulate nanotechnology. Blog | Follow @MichaelGFierce

> Edwards slips as so-so outlook leaves investors underwhelmed. Report

> Covidien flips surgical sealants to Integra for $235M. More

Pharma News

@FiercePharma:  isn't getting post-marketing data on fast-tracked drugs, per JAMA. Required studies undone or unreported. JAMA report | Follow @FiercePharma

@CarlyHFierce: Biogen's Tecfidera drives rosy Q3 results, higher forecast. ICYMI yesterday | Follow @CarlyHFierce

> Vertex to slash 370 jobs in shift away from hep C drug. News

> Sunk by generics, Pfizer clings to emerging markets, cancer meds. Article

Pharma Manufacturing News

@EricPFierce: What drugs are up for grabs by generic makers next year? Here's the FiercePharma list of 2014 patent losses. | Follow @EricPFierce

> Wockhardt profits crater after U.S., U.K. plant bans. More

> Manufacturing glitch leaves Novo insulin cartridges with bad fills. Report

> Gilead expanding facility that makes highly anticipated hep C drug. Story

> India's plan to inspect China plants stalled. Article

Biotech Research News

@EmilyMFierce: I took a look at 5 promising preclinical drug programs across industry/academia for this latest report. Feature | Follow @EmilyMFierce

> Fast-acting antidepressants discovered. Report

> New obstacle found in search for HIV/AIDS cure. Item

> Certain microRNAs might be viable Alzheimer's targets. Article

> CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact. Story

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.